Back Login to subscribe 🔔 Set Alert

BIIB Biogen Inc. Common Stock

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Why Is Biogen Stock Falling Tuesday?	72.95%
	Eisai And Biogen Present Real‑World LEADER Study Data At AAIC Showing Nearly 83% Of Early Alzheimer’s Patients Remained Stable Or Improved On LEQEMBI Therapy Over ~17 Months, With Consistent Results Across Diverse Groups.	57.82%
	Biogen shares are trading lower. The company presented Phase 2 CELIA data at AAIC showing meaningful clinical outcomes and robust tau reduction with investigational Alzheimer’s therapy diranersen, with plans to advance into Phase 3.	82.21%
	Biogen's Diranersen Demonstrates Efficacy Throughout All Doses In Phase 2 CELIA Trial Of Alzheimer’s Disease; Consistent Efficacy Seen Across Multiple Prespecified Secondary Endpoints Including Clinical Dementia Rating Sum Of Boxes	82.19%
	Eisai Co And Biogen Receive FDA's Approval For A Supplemental Biologics License Application For A Once-Weekly Lecanemab-Irmb Subcutaneous Injection As An Initiation Dose For The Treatment Of Early Alzheimer’s Disease; U.S. Launch Of LEQEMBI IQLIK As An Initiation Dose Planned For Late August 2026	83.23%
	FDA Grants Approval For At-Home Starting Dose For Alzheimer's Treatment Leqembi	90.03%
	Biogen shares are trading higher after Truist Securities upgraded the stock from Hold to Buy rating and raised its price target from $190 to $235.	95.21%
	This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday	74.96%
	Truist Securities Upgrades Biogen to Buy, Raises Price Target to $235	86.03%
	Reported Sunday, Eisai And Biogen's LEQEMBI SC-AI Data At AAIC 2026 Reinforces Case For Early, Continuous Alzheimer's Treatment With Greater Administration Optionality	72.43%

1
2
3
›